Record Information |
---|
Version | 5.0 |
---|
Status | Detected and Quantified |
---|
Creation Date | 2006-08-12 23:33:54 UTC |
---|
Update Date | 2022-03-07 02:49:19 UTC |
---|
HMDB ID | HMDB0003550 |
---|
Secondary Accession Numbers | - HMDB0005997
- HMDB03550
- HMDB05997
|
---|
Metabolite Identification |
---|
Common Name | Calcidiol |
---|
Description | Calcidiol, also known as 25(OH)D3 or rayaldee, belongs to the class of organic compounds known as vitamin d and derivatives. Vitamin D and derivatives are compounds containing a secosteroid backbone, usually secoergostane or secocholestane. Thus, calcidiol is considered to be a secosteroid lipid molecule. Calcidiol is a very hydrophobic molecule, practically insoluble (in water), and relatively neutral. Calcidiol is a potentially toxic compound. |
---|
Structure | C[C@H](CCCC(C)(C)O)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C InChI=1S/C27H44O2/c1-19-10-13-23(28)18-22(19)12-11-21-9-7-17-27(5)24(14-15-25(21)27)20(2)8-6-16-26(3,4)29/h11-12,20,23-25,28-29H,1,6-10,13-18H2,2-5H3/b21-11+,22-12-/t20-,23+,24-,25+,27-/m1/s1 |
---|
Synonyms | Value | Source |
---|
(3beta,5Z,7E)-9,10-Secocholesta-5,7,10(19)-triene-3,25-diol | ChEBI | (3S,5Z,7E)-9,10-Secocholesta-5,7,10-triene-3,25-diol | ChEBI | (5Z,7E)-(3S)-9,10-Secocholesta-5,7,10(19)-triene-3,25-diol | ChEBI | 25(OH)D3 | ChEBI | 25-Hydroxycholecalciferol | ChEBI | 25-Hydroxyvitamin D3 | ChEBI | 3-{2-[1-(5-hydroxy-1,5-dimethyl-hexyl)-7a-methyl-octahydro-inden-4-ylidene]-ethylidene}-4-methylene-cyclohexanol | ChEBI | Calcifediol | ChEBI | Calcifediol anhydrous | ChEBI | Calcifediolum | ChEBI | Rayaldee | ChEBI | (3S,5Z,7E)-9,10-Seco-5,7,10(19)-cholestatriene-3,25-diol | Kegg | (3b,5Z,7E)-9,10-Secocholesta-5,7,10(19)-triene-3,25-diol | Generator | (3Β,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol | Generator | 25-Hydroxy-cholecalciferol | HMDB | 5,6-cis-25-Hydroxyvitamin D3 | HMDB | 9,10-Secocholesta-5,7,10(19)-triene-3b,25-diol | HMDB | Calderol | HMDB | Didrogyl | HMDB | Hidroferol | HMDB | 25 Hydroxyvitamin D3 | HMDB | Calcifediol, (3 beta,5E,7E)-isomer | HMDB | Monohydrate, 25-hydroxycholecalciferol | HMDB | 25-Hydroxycholecalciferol monohydrate | HMDB | Anhydrous, calcifediol | HMDB | Organon brand OF calcifediol | HMDB | 25 Hydroxyvitamin D 3 | HMDB | 25-Hydroxyvitamin D 3 | HMDB | Aventis brand OF calcifediol | HMDB | Calcifediol aventis brand | HMDB | Calcifediol organon brand | HMDB | Dedrogyl | HMDB | 25 Hydroxycholecalciferol | HMDB | 25 Hydroxycholecalciferol monohydrate | HMDB | Calcifediol faes brand | HMDB | Calcifediol, (3 alpha,5Z,7E)-isomer | HMDB | Faes brand OF calcifediol | HMDB | Calcidiol | MeSH |
|
---|
Chemical Formula | C27H44O2 |
---|
Average Molecular Weight | 400.6371 |
---|
Monoisotopic Molecular Weight | 400.334130652 |
---|
IUPAC Name | (1S,3Z)-3-{2-[(1R,3aS,4E,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-octahydro-1H-inden-4-ylidene]ethylidene}-4-methylidenecyclohexan-1-ol |
---|
Traditional Name | 25-hydroxyvitamin D3 |
---|
CAS Registry Number | 19356-17-3 |
---|
SMILES | C[C@H](CCCC(C)(C)O)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C |
---|
InChI Identifier | InChI=1S/C27H44O2/c1-19-10-13-23(28)18-22(19)12-11-21-9-7-17-27(5)24(14-15-25(21)27)20(2)8-6-16-26(3,4)29/h11-12,20,23-25,28-29H,1,6-10,13-18H2,2-5H3/b21-11+,22-12-/t20-,23+,24-,25+,27-/m1/s1 |
---|
InChI Key | JWUBBDSIWDLEOM-DTOXIADCSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as vitamin d and derivatives. Vitamin D and derivatives are compounds containing a secosteroid backbone, usually secoergostane or secocholestane. |
---|
Kingdom | Organic compounds |
---|
Super Class | Lipids and lipid-like molecules |
---|
Class | Steroids and steroid derivatives |
---|
Sub Class | Vitamin D and derivatives |
---|
Direct Parent | Vitamin D and derivatives |
---|
Alternative Parents | |
---|
Substituents | - Triterpenoid
- Tertiary alcohol
- Cyclic alcohol
- Secondary alcohol
- Organic oxygen compound
- Hydrocarbon derivative
- Organooxygen compound
- Alcohol
- Aliphatic homopolycyclic compound
|
---|
Molecular Framework | Aliphatic homopolycyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | |
---|
Disposition | |
---|
Process | |
---|
Role | |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | Not Available | Not Available |
|
---|
Experimental Chromatographic Properties | Experimental Collision Cross Sections |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Calcidiol,1TMS,isomer #1 | C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)(C)O[Si](C)(C)C | 3382.8 | Semi standard non polar | 33892256 | Calcidiol,1TMS,isomer #2 | C=C1CC[C@H](O[Si](C)(C)C)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)(C)O | 3266.7 | Semi standard non polar | 33892256 | Calcidiol,2TMS,isomer #1 | C=C1CC[C@H](O[Si](C)(C)C)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)(C)O[Si](C)(C)C | 3361.3 | Semi standard non polar | 33892256 | Calcidiol,1TBDMS,isomer #1 | C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)(C)O[Si](C)(C)C(C)(C)C | 3612.5 | Semi standard non polar | 33892256 | Calcidiol,1TBDMS,isomer #2 | C=C1CC[C@H](O[Si](C)(C)C(C)(C)C)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)(C)O | 3467.1 | Semi standard non polar | 33892256 | Calcidiol,2TBDMS,isomer #1 | C=C1CC[C@H](O[Si](C)(C)C(C)(C)C)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)(C)O[Si](C)(C)C(C)(C)C | 3829.2 | Semi standard non polar | 33892256 |
|
---|
Spectra |
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental GC-MS | GC-MS Spectrum - Calcidiol GC-MS (2 TMS) | splash10-001i-2900000000-33a8e563016d6e2e358e | 2014-06-16 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Calcidiol GC-MS (2 TMS) | splash10-00lr-2900000000-f6bedf68127696063061 | 2014-06-16 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Calcidiol GC-MS (Non-derivatized) | splash10-001i-2900000000-33a8e563016d6e2e358e | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Calcidiol GC-MS (Non-derivatized) | splash10-00lr-2900000000-f6bedf68127696063061 | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Calcidiol GC-MS (Non-derivatized) - 70eV, Positive | splash10-0ab9-3029000000-4c75b5cfbc422ba2a344 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Calcidiol GC-MS (2 TMS) - 70eV, Positive | splash10-003r-1403290000-a8eb9294a6df1ce864d2 | 2017-10-06 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Calcidiol GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Calcidiol GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Calcidiol 10V, Positive-QTOF | splash10-00lr-0119100000-d3e0a5d2ecb614d781d4 | 2016-06-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Calcidiol 20V, Positive-QTOF | splash10-0api-0369000000-146e7a23795c22f5b836 | 2016-06-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Calcidiol 40V, Positive-QTOF | splash10-0kai-5296000000-412b0c2da61c93271acd | 2016-06-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Calcidiol 10V, Negative-QTOF | splash10-0002-0009000000-ef5150b1dccaed2f9543 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Calcidiol 20V, Negative-QTOF | splash10-000t-0009000000-4b22b5c88dc06c01fe89 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Calcidiol 40V, Negative-QTOF | splash10-00si-2229000000-f4037186ef5a21a16859 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Calcidiol 10V, Negative-QTOF | splash10-0002-0009000000-21157f4aa99daf697271 | 2021-09-22 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Calcidiol 20V, Negative-QTOF | splash10-0002-0009000000-cac0e3874faca9c17f03 | 2021-09-22 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Calcidiol 40V, Negative-QTOF | splash10-01ot-0339000000-37442d1a71c50883b377 | 2021-09-22 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Calcidiol 10V, Positive-QTOF | splash10-001i-0549100000-68f99126c8d8b4ca7eb7 | 2021-09-22 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Calcidiol 20V, Positive-QTOF | splash10-0g4i-5594100000-433f2a913eb577e9397a | 2021-09-22 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Calcidiol 40V, Positive-QTOF | splash10-0ab9-1940000000-e03ff70cb44513aa8ae8 | 2021-09-22 | Wishart Lab | View Spectrum |
|
---|
Biological Properties |
---|
Cellular Locations | - Cytoplasm
- Extracellular
- Membrane (predicted from logP)
- Mitochondria
|
---|
Biospecimen Locations | |
---|
Tissue Locations | - Epidermis
- Kidney
- Ovary
- Prostate
- Testis
|
---|
Pathways | |
---|
Normal Concentrations |
---|
| |
Blood | Detected and Quantified | 0.0422 uM | Adult (>18 years old) | Both | Normal | | details | Blood | Detected and Quantified | 0.035 uM | Adult (>18 years old) | Female | Normal | | details | Blood | Detected and Quantified | 0.0300-0.155 uM | Not Specified | Not Specified | Normal | | details | Blood | Detected and Quantified | 0.042 uM | Adult (>18 years old) | Female | Normal | | details | Blood | Detected and Quantified | 0.044 uM | Adult (>18 years old) | Female | Normal | | details | Blood | Detected and Quantified | 0.0547 uM | Adult (>18 years old) | Female | Normal | | details | Blood | Detected and Quantified | 0.0689 (0.0459-0.0919) uM | Adult (>18 years old) | Both | Normal | | details | Blood | Detected and Quantified | 0.057 uM | Adult (>18 years old) | Female | Normal | | details | Blood | Detected and Quantified | 0.0634 uM | Adult (>18 years old) | Female | Normal | | details | Blood | Detected and Quantified | 0.13 (0.13-0.14) uM | Adult (>18 years old) | Both | Normal | | details | Blood | Detected and Quantified | 0.064 uM | Adult (>18 years old) | Female | Normal | | details | Blood | Detected and Quantified | 0.074 uM | Adult (>18 years old) | Female | Normal | | details | Blood | Detected and Quantified | 0.08 uM | Adult (>18 years old) | Female | Normal | | details | Blood | Detected and Quantified | 0.081 uM | Adult (>18 years old) | Female | Normal | | details | Blood | Detected and Quantified | 0.0577 uM | Adult (>18 years old) | Both | Normal | | details | Blood | Detected and Quantified | 0.0600 +/- 0.0222 uM | Adult (>18 years old) | Female | Normal | | details | Blood | Detected and Quantified | 0.0678 +/- 0.0222 uM | Adult (>18 years old) | Female | Normal | | details | Blood | Detected and Quantified | 0.0469 uM | Adult (>18 years old) | Both | Normal | | details | Blood | Detected and Quantified | 0.0600 +/- 0.0146 uM | Adult (>18 years old) | Both | Normal | | details | Blood | Detected and Quantified | 0.07 uM | Adult (>18 years old) | Female | Normal | | details | Blood | Detected and Quantified | 0.078 uM | Adult (>18 years old) | Female | Normal | | details | Blood | Detected and Quantified | 0.0831 uM | Adult (>18 years old) | Female | Normal | | details | Blood | Detected and Quantified | 0.0700 +/- 0.0310 uM | Adult (>18 years old) | Female | Normal | | details | Blood | Detected and Quantified | 0.0730 +/- 0.0310 uM | Adult (>18 years old) | Female | Normal | | details | Blood | Detected and Quantified | 0.095 uM | Adult (>18 years old) | Male | Normal | | details | Blood | Detected and Quantified | 0.108 uM | Adult (>18 years old) | Male | Normal | | details | Blood | Detected and Quantified | 0.0790 +/- 0.0340 uM | Adult (>18 years old) | Male | Normal | | details | Blood | Detected and Quantified | 0.0830 +/- 0.0320 uM | Adult (>18 years old) | Male | Normal | | details | Blood | Detected and Quantified | 0.0245 +/- 0.023 uM | Adult (>18 years old) | Both | Normal | | details | Blood | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details | Blood | Detected and Quantified | >0.0749 uM | Not Specified | Not Specified | Normal | | details | Urine | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details | Urine | Detected and Quantified | 0.092 +/- 0.0037 umol/mmol creatinine | Adult (>18 years old) | Both | Normal | | details |
|
---|
Abnormal Concentrations |
---|
| |
Blood | Detected and Quantified | 0.0137 uM | Infant (0-1 year old) | Female | Pyroglutamic aciduria | | details | Blood | Detected and Quantified | 0.044 (0.013-0.074) uM | Adult (>18 years old) | Both | Anephrism | | details | Blood | Detected and Quantified | 0.0549 +/- 0.0225 uM | Children (1-13 years old) | Both | Adrenal hyperplasia, congenital, due to 3-beta-hydroxysteroid dehydrogenase 2 deficiency | | details | Blood | Detected and Quantified | 0.0449 +/- 0.00749 uM | Children (1-13 years old) | Both | Adrenal hyperplasia, congenital, due to 3-beta-hydroxysteroid dehydrogenase 2 deficiency | | details | Blood | Detected and Quantified | 0.0599 +/- 0.0200 uM | Children (1-13 years old) | Both | Adrenal hyperplasia, congenital, due to 3-beta-hydroxysteroid dehydrogenase 2 deficiency | | details | Blood | Detected and Quantified | 0.0704 uM | Adult (>18 years old) | Male | Bartter Syndrome, Type 4A, Neonatal, with Sensorineural Deafness | | details | Urine | Detected and Quantified | 0.0099 +/- 0.0019 umol/mmol creatinine | Adult (>18 years old) | Both | Nephrotic syndrome | | details |
|
---|
Associated Disorders and Diseases |
---|
Disease References | Anephric patients |
---|
- Shepard RM, Horst RL, Hamstra AJ, DeLuca HF: Determination of vitamin D and its metabolites in plasma from normal and anephric man. Biochem J. 1979 Jul 15;182(1):55-69. [PubMed:227368 ]
| Adrenal hyperplasia, congenital, due to 3-beta-hydroxysteroid dehydrogenase 2 deficiency |
---|
- Benkert AR, Young M, Robinson D, Hendrickson C, Lee PA, Strauss KA: Severe Salt-Losing 3beta-Hydroxysteroid Dehydrogenase Deficiency: Treatment and Outcomes of HSD3B2 c.35G>A Homozygotes. J Clin Endocrinol Metab. 2015 Aug;100(8):E1105-15. doi: 10.1210/jc.2015-2098. Epub 2015 Jun 16. [PubMed:26079780 ]
| Bartter Syndrome, Type 4A, Neonatal, with Sensorineural Deafness |
---|
- Heilberg IP, Totoli C, Calado JT: Adult presentation of Bartter syndrome type IV with erythrocytosis. Einstein (Sao Paulo). 2015 Oct-Dec;13(4):604-6. doi: 10.1590/S1679-45082015RC3013. Epub 2015 Oct 30. [PubMed:26537508 ]
| Nephrotic syndrome |
---|
- Goldstein DA, Haldimann B, Sherman D, Norman AW, Massry SG: Vitamin D metabolites and calcium metabolism in patients with nephrotic syndrome and normal renal function. J Clin Endocrinol Metab. 1981 Jan;52(1):116-21. [PubMed:6969729 ]
|
|
---|
Associated OMIM IDs | - 201810 (Adrenal hyperplasia, congenital, due to 3-beta-hydroxysteroid dehydrogenase 2 deficiency)
- 602522 (Bartter Syndrome, Type 4A, Neonatal, with Sensorineural Deafness)
|
---|
External Links |
---|
DrugBank ID | DB00146 |
---|
Phenol Explorer Compound ID | Not Available |
---|
FooDB ID | FDB021782 |
---|
KNApSAcK ID | C00040805 |
---|
Chemspider ID | 4446820 |
---|
KEGG Compound ID | C01561 |
---|
BioCyc ID | Not Available |
---|
BiGG ID | 2289142 |
---|
Wikipedia Link | Calcifediol |
---|
METLIN ID | 6949 |
---|
PubChem Compound | 5283731 |
---|
PDB ID | Not Available |
---|
ChEBI ID | 17933 |
---|
Food Biomarker Ontology | Not Available |
---|
VMH ID | 25HVITD3 |
---|
MarkerDB ID | MDB00000426 |
---|
Good Scents ID | Not Available |
---|
References |
---|
Synthesis Reference | Mascarenas, J. L.; Mourino, A.; Castedo, L. Studies on the synthesis of side-chain hydroxylated metabolites of vitamin D. 3. Synthesis of 25-ketovitamin D3 and 25-hydroxyvitamin D3. Journal of Organic Chemistry (1986), 51(8), 1269-72. |
---|
Material Safety Data Sheet (MSDS) | Download (PDF) |
---|
General References | - Flanagan JN, Young MV, Persons KS, Wang L, Mathieu JS, Whitlatch LW, Holick MF, Chen TC: Vitamin D metabolism in human prostate cells: implications for prostate cancer chemoprevention by vitamin D. Anticancer Res. 2006 Jul-Aug;26(4A):2567-72. [PubMed:16886665 ]
- Shepard RM, Horst RL, Hamstra AJ, DeLuca HF: Determination of vitamin D and its metabolites in plasma from normal and anephric man. Biochem J. 1979 Jul 15;182(1):55-69. [PubMed:227368 ]
- Passadakis P, Ersoy F, Tam P, Memmos D, Siamopoulos K, Ozener C, Akcicek F, Camsari T, Ates K, Ataman R, Vlachojannis J, Dombros N, Utas C, Akpolat T, Bozfakioglu S, Wu GG, Karayaylali I, Arinsoy T, Stathakis C, Yavuz M, Tsakiris D, Dimitriades A, Yilmaz ME, Gultekin M, Karayalcin B, Challa A, Polat N, Oreopoulos DG: Serum levels of prostate-specific antigen and vitamin D in peritoneal dialysis patients. Adv Perit Dial. 2004;20:203-8. [PubMed:15384827 ]
- Park SB, Suh DH, Youn JI: A pilot study to assess the safety and efficacy of topical calcipotriol treatment in childhood psoriasis. Pediatr Dermatol. 1999 Jul-Aug;16(4):321-5. [PubMed:10469423 ]
- Haden ST, Fuleihan GE, Angell JE, Cotran NM, LeBoff MS: Calcidiol and PTH levels in women attending an osteoporosis program. Calcif Tissue Int. 1999 Apr;64(4):275-9. [PubMed:10089217 ]
- Gacad MA, Adams JS: Proteins in the heat shock-70 family specifically bind 25-hydroxyvitamin D3 and 17beta-estradiol. J Clin Endocrinol Metab. 1998 Apr;83(4):1264-7. [PubMed:9543154 ]
- Feingold KR, Williams ML, Pillai S, Menon GK, Halloran BP, Bikle DD, Elias PM: The effect of vitamin D status on cutaneous sterologenesis in vivo and in vitro. Biochim Biophys Acta. 1987 Sep 14;930(2):193-200. [PubMed:3040120 ]
- DeLuca HF: Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr. 2004 Dec;80(6 Suppl):1689S-96S. [PubMed:15585789 ]
- Brunk E, Sahoo S, Zielinski DC, Altunkaya A, Drager A, Mih N, Gatto F, Nilsson A, Preciat Gonzalez GA, Aurich MK, Prlic A, Sastry A, Danielsdottir AD, Heinken A, Noronha A, Rose PW, Burley SK, Fleming RMT, Nielsen J, Thiele I, Palsson BO: Recon3D enables a three-dimensional view of gene variation in human metabolism. Nat Biotechnol. 2018 Mar;36(3):272-281. doi: 10.1038/nbt.4072. Epub 2018 Feb 19. [PubMed:29457794 ]
|
---|